Asia
Dizal Pharma to Present Research Results for Three Drugs At American Society of Clinical Oncology's Annual Meeting
Dizal (Jiangsu) Pharmaceutical (SHA:688192) said it will present the latest research results of sunvozertinib tablets, golidocitinib capsules and DZD6008 at the annual meeting of the American Society of Clinical Oncology, according to a Wednesday filing on the Shanghai bourse.Sunvozertinib and DZD6008 are both developed as treatments for non-small cell lung cancer, while golidocitinib is for T-cell lymphoma. Studies has shown positive results, especially in DZD6008, which had significant antitumor activity and was safe to use.The biotechnology company's shares rose less than 2% during the midday trade.
SHA:688192
